Institutional & Family Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Institutional & Family Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16	Closed	–	–	977
2021 Q3	$0	Sell	16 -35	-69%	-$966	﹤0.01%	1004
2021 Q2	$2K	Buy	51 +14	+38%	+$429	﹤0.01%	857
2021 Q1	$1K	Sell	37 -22	-37%	-$562	﹤0.01%	920
2020 Q4	$1K	Sell	59 -2	-3%	-$44	﹤0.01%	858
2020 Q3	$1K	Hold	61	–	–	﹤0.01%	823
2020 Q2	$2K	Sell	61 -18	-23%	-$388	﹤0.01%	737
2020 Q1	$1K	Hold	79	–	–	﹤0.01%	797
2019 Q4	$2K	Hold	79	–	–	﹤0.01%	778
2019 Q3	$1K	Buy	+79	New	+$1.13K	﹤0.01%	819

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Institutional & Family Asset Management's DRNA Position: Q4 2021 in Review

Institutional & Family Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 16 shares.

Institutional & Family Asset Management first reported a position in DRNA in Q3 2019 and held it in 9 quarters. The position peaked at $2K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Institutional & Family Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Institutional & Family Asset Management sold 16 Dicerna Pharmaceuticals, Inc. shares in Q4 2021.
Institutional & Family Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 9 quarters.
Institutional & Family Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $2K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Institutional & Family Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.